Benzinga | Jan 5, 2021 08:05AM EST

Trinity Biotech Announces CE Mark Of Its Covid-19 IgG ELISA Antibody Test

DUBLIN, Ireland, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB) has achieved CE Mark approval and registration for its Covid-19 IgG ELISA antibody test, the Captia(tm) SARS-CoV-2 IgG ELISA.



Trinity Biotech has launched the test in countries throughout the European Union as well as other countries that recognise the CE Mark designation. This is in addition to our launch of the product in the US following submission under the FDAs Emergency Use Authorisation pathway.